Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ABBV-142 · 2 trials · 2 indications
FVC is a test that measures the total amount of air a person can fully exhale from their lungs after a deep inhalation. A low FVC can demonstrate reduced lung capacity.
An adverse event (AE) is defined as any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product which does not necessarily have a causal relationship with the treatment. The investigator assesses the relationship of each event to the use of study drug.
An AE is defined as any untoward medical occurrence in a patient or clinical investigation in which a participant is administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment.
Cmax of ABBV-142 will be assessed.
Tmax of ABBV-142 will be assessed.
AUCt of ABBV-142 will be determined.
AUCinf of ABBV-142 will be assessed.
Terminal phase elimination rate constant (β) of ABBV-142 will be assessed.
Terminal phase elimination half-life (t1/2) of ABBV-142 will be assessed.
Dose normalized Cmax of ABBV-142 will be assessed.
Dose normalized AUC of ABBV-142 will be assessed.
| Arm | Type | Description |
|---|---|---|
| Substudy 1: ABBV-142 | EXPERIMENTAL | Participants will receive ABBV-142 for 52 week during double-blind treatment period. Eligible participants may receive ABBV-142 for 52 weeks during open-label treatment period. |
| Substudy 1: Placebo for ABBV-142 | PLACEBO_COMPARATOR | Participants will receive placebo for ABBV-142 for 52 week during double-blind treatment period. Eligible participants may receive ABBV-142 for 52 weeks during open-label treatment period. |
| Part 1: Group 1 | EXPERIMENTAL | Participants will receive ABBV-142 Dose A or Placebo on Day 1. |
| Part 1: Group 2 | EXPERIMENTAL | Participants will receive ABBV-142 Dose B or Placebo on Day 1. |
| Part 1: Group 3 | EXPERIMENTAL | Participants will receive ABBV-142 Dose C or Placebo on Day 1. |
| Part 1: Group 4 | EXPERIMENTAL | Participants will receive ABBV-142 Dose D or Placebo on Day 1. |
| Part 1: Group 5 (Optional) | EXPERIMENTAL | Participants will receive ABBV-142 Dose TBD or Placebo on Day 1. |
| Part 2: Group 6 | EXPERIMENTAL | Participants will receive ABBV-142 Dose B or Placebo on Day 1. |
| Part 2: Group 7 | EXPERIMENTAL | Participants will receive ABBV-142 Dose C or Placebo on Day 1. |
| Part 3: Group 8 | EXPERIMENTAL | Han Chinese participants will receive ABBV-142, dose to be determined, or Placebo on Day 1. |
| Part 3: Group 9 | EXPERIMENTAL | Japanese participants will receive ABBV-142, dose to be determined, or Placebo on Day 1. |
| Name | Type | Description |
|---|---|---|
| ABBV-142 | DRUG | ABBV-142 |
| Placebo for ABBV-142 | DRUG | Placebo for ABBV-142 |
| Placebo | DRUG | IV Infusion |
Inclusion Criteria: \- Diagnosis of Idiopathic Pulmonary Fibrosis (IPF) within 7 years prior to screening, confirmed by the investigator at screening that is supported by centrally read chest high-resolution computed tomography (HRCT) obtained within 12 months of the screening visit and verificatio...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Bristol-Myers Squibb Company | BMY | 2 | PHASE3 | BMS-986278 |
| United Therapeutics Corporation | UTHR | 2 | PHASE3 | Treprostinil |
| AbbVie, Inc. | ABBV | 2 | PHASE2 | ABBV-142 |
| PureTech Health PLC Sponsored ADR | PRTC | 2 | PHASE3 | Deupirfenidone, Pirfenidone |
| Syndax Pharmaceuticals Inc | SNDX | 1 | PHASE2 | Axatilimab |
| Contineum Therapeutics, Inc. Class A | CTNM | 1 | PHASE2 | PIPE-791 Dose A, PIPE-791 Dose B |
| Rein Therapeutics, Inc | RNTX | 1 | PHASE2 | LTI-03 |
| Sunshine Biopharma Incorporated | SBFM | 2 | PHASE3 | HEC585, Pirfenidone |
| Cumberland Pharmaceuticals Inc. | CPIX | 1 | PHASE2 | Ifetroban |
| Avalyn Pharma Inc | AVLN | 3 | PHASE2 | AP01 |
ABBV-142 is an investigational small molecule being studied for the treatment of Idiopathic Pulmonary Fibrosis (IPF). It is also being evaluated in healthy volunteers to assess how the drug moves through the body. The drug is administered via subcutaneous injection or intravenous infusion.
ABBV-142 is being developed by AbbVie Inc., a biopharmaceutical company traded on the New York Stock Exchange under the ticker ABBV. The company is conducting clinical trials to evaluate the safety and efficacy of this investigational drug.
ABBV-142 is in Phase 1 clinical development for healthy volunteers and Phase 2 clinical development for Idiopathic Pulmonary Fibrosis. The Phase 1 study has been completed, while the Phase 2 study is currently recruiting participants. It is not yet approved by regulatory authorities.
ABBV-142 is being studied in two clinical trials. NCT06774313 is a completed Phase 1 study in healthy volunteers in the United States. NCT07230288 is a recruiting Phase 2 study in adults with Idiopathic Pulmonary Fibrosis, conducted across multiple countries including the US, Australia, Japan, and European nations.
ABBV-142 is a small molecule, but its specific molecular target has not been disclosed. The drug is being studied for its potential to treat Idiopathic Pulmonary Fibrosis, a condition characterized by progressive scarring of the lungs. Its mechanism of action is not publicly detailed.